title: Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation.
abstract: The aim of this study was to assess the economic impact of the use of granulocyte colony stimulating factor (RHu-G-CSF) in patients treated by autologous bone marrow transplantation (ABMT) for lymphomas. Demographic, clinical and economic data were collected retrospectively from a random sample of 55 patients in four French centres who underwent ABMT (usual care) without or with administration of RHu-G-CSF over a period of 100 days post-ABMT. The patients treated with RHu-G-CSF had a shorter period of infection, neutropenia and severe neutropenia (P < 0.05) when compared with usual care recipients. Compared to usual care, the use of G-CSF was associated with a 3% reduction in total cost of care for ABMT over 100 days post-ABMT or US$1316, including RHu-G-CSF cost. This cost reduction was mainly due to a reduced length of stay in hospital and fewer laboratory tests.
authors: Benefit Research Group, Gennevilliers, France.
authors: E
authors: E
authors: Souêtre
authors: W
authors: W
authors: Qing
authors: P F
authors: PF
authors: Pénelaud
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation / Q000191:economics*; D005260:Female; D005500:Follow-Up Studies; D005602:France; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D017048:Health Care Costs; D006801:Humans; D008223:Lymphoma / Q000191:economics / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000517:prevention & control; D009894:Opportunistic Infections / Q000517:prevention & control; D011897:Random Allocation; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor